Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. - Wikidata - wikimedia - TriplyDB

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

http://www.wikidata.org/entity/Q34253290

about

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL New Era of Lipid-Lowering Drugs Discovery and refinement of loci associated with lipid levels.Genetic variants in CETP increase risk of intracerebral hemorrhage.CETP inhibitors and cardiovascular disease: Time to think again.Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit.Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors.Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.Effects of whole grain, fish and bilberries on serum metabolic profile and lipid transfer protein activities: a randomized trial (Sysdimet).Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice.Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration.New molecular insights into CETP structure and function: a review.Human serum preβ1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases.Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.High density lipoprotein: a therapeutic target in type 2 diabetes.Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages--a novel anti-inflammatory action of alcohol Disease-associated marked hyperalphalipoproteinemia.Lymphatic transport of high-density lipoproteins and chylomicrons.Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Genetics of HDL-C: a causal link to atherosclerosis?Demystifying the management of hypertriglyceridaemia.Oral retinoids and plasma lipids.Ongoing challenges for pharmacotherapy for dyslipidemia.Chemical Genetic Approaches for the Investigation of Neutral Lipid Metabolism.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.Plaque imaging to refine indications for emerging lipid-lowering drugs.Hepatic expression of inflammatory genes and microRNAs in pigs with high "cholesteryl ester transfer protein" (CETP) activity.Moringa Leaves Prevent Hepatic Lipid Accumulation and Inflammation in Guinea Pigs by Reducing the Expression of Genes Involved in Lipid Metabolism.A novel swine model for evaluation of dyslipidemia and atherosclerosis induced by human CETP overexpression.CETP Lowers TLR4 Expression Which Attenuates the Inflammatory Response Induced by LPS and Polymicrobial Sepsis.Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?New lipid and lipoprotein targets for the treatment of cardiometabolic diseases.High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol.HDL--is it too big to fail?

P2860

Q26801507-DC1032D0-B23C-4D48-867E-7DF313D965D0 Q28072298-733B7278-73DD-4EF5-B586-60CB7D76F776 Q28661470-92BF2D5D-C551-481C-97E0-2A7A69A501F9 Q30275688-1856CC3E-55A6-414F-BF7E-075B131969E5 Q34109100-9997456F-5B2C-47F2-BCCA-DB5E503AF220 Q34571030-C8739EEC-4A7B-4BA9-9C69-95BDC5AC3B37 Q34653513-25BAC866-9F5D-42E8-9226-27B2E540F67A Q34708105-E280E3AA-3CB4-493A-93AE-B0CC532C4DEA Q34858025-8CB461F2-AC3B-4596-B8E4-BE1428C81990 Q35108988-88B7059F-FEE0-4EAE-89E5-FD022AA195F2 Q35776623-55AFF7C2-10E5-4B8E-9E1F-64EE54EB6292 Q35923466-DEFE7144-C8B6-4C65-99E2-E9A98D4C1EA3 Q35950004-180718F4-05DD-410D-9001-F766473026D0 Q36209833-4AF702C8-EA03-4028-8BD3-A581CDF99DF3 Q36520363-6F4C8197-AD80-4857-978D-7F6CF1C48099 Q36907281-8180731A-0BAA-4125-B1A3-FFCBCEEB6196 Q37038670-6F7E3ED8-6C96-4AB9-804A-8803C0CDEDF1 Q37239358-C246BC41-88CB-436A-A6D4-92386D62D256 Q37264429-5D8E084A-D975-4C83-9DF0-D2DD1DF1C8AB Q37297453-4E9B3E2F-76D8-4010-9CE5-0A515A7AB380 Q37434051-4E0DC10A-4114-4B1B-8C6D-4FE623A51650 Q37602219-AB1ECF25-ED63-4B31-B01C-EE4CE8F38F0A Q37695401-3B23DEA0-F269-42D9-AB73-977EC1D24B57 Q38099536-DDD0823F-406C-4A9F-9E23-9345394D2F61 Q38141575-6B2F58DD-864A-45F6-B02B-F0D27685C1E9 Q38149925-ED5719D5-0C15-4D1D-BBA7-5590986EEDBC Q38283386-E1D10E67-9D85-41B7-8603-5D62F0E008DD Q38682493-3E737240-ECD4-4DB9-A06E-D841EFFB067A Q38707328-378895AD-BF11-4FBE-8088-08216A375E73 Q38762941-D082A62C-D251-428E-A645-6166DE34D4BC Q39000038-9230884A-0374-436C-993F-03AA0C41568B Q39725525-F656162D-1AD5-4017-83A3-027429C3AC25 Q41181133-3D0DFB1D-B8ED-4EEF-A16D-BB3FE21508F2 Q41278125-C9620104-CFFD-4AF6-A45F-AFA9995BDD88 Q42103732-7E0F5A28-0E91-403C-AA6B-B75A7E532BF7 Q43204658-71926337-FB6C-4A0C-BBEE-380E157DEAC8 Q43237185-47B10D62-11B1-456A-9F36-FB55A26CF43E Q43498643-FF825FC6-3B9D-4D55-89D0-CF46A129B199 Q45870343-9D2E91DB-EEC3-4D7D-A246-076F7281930B Q46866176-4E128AB7-BE1B-40D7-853F-E0A9DA36730B

P2860

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

http://www.wikidata.org/entity/Q34253290

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@ast

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@en

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@nl

type

label

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@ast

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@en

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@nl

prefLabel

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@ast

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@en

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@nl

P1433

Q34253290-E475F75D-B2C7-4CD8-B9C3-34B619425A5D

P1476

Q34253290-654FF190-A2DF-4D0F-8B78-AADD726A0C8B

P2093

Q34253290-4BB2BAB7-591F-45D0-A6ED-933742F17B56

Q34253290-6D673C2E-E721-4D2C-B12D-0F3996CA6276

P2860

Q34253290-02BFC65C-9DC0-4CFC-A21D-A15C9C98A61E

Q34253290-07F7F329-8F39-405B-A7EF-E20921EABDEE

Q34253290-0DD6E7C2-7C30-4035-8727-60F3C5082253

Q34253290-0F297FC1-9069-4213-AE12-ADA3E38E44D8

Q34253290-17E3417E-84E6-4D21-A8FB-3F079B47D68C

Q34253290-19823D7E-868E-4825-B7B6-5EF87D8CE286

Q34253290-1F69B2D3-8086-4FA0-88E9-C45A7CEE290B

Q34253290-239DA0A1-67C8-4180-B473-09003E18F973

Q34253290-2875BAE8-BBA0-4D43-A238-79D46BAA3C36

Q34253290-2C74F655-AADE-4B72-A1E7-CD7D1FB3F135

P304

Q34253290-2063D214-5814-4183-A5AC-93B4378DD850

P31

Q34253290-0CE3BE2F-3D42-4E2F-90F6-AEFF76BEB229

P356

Q34253290-A43E654A-AE28-4D85-A11D-2D5EB91B5504

P433

Q34253290-65F55321-FF11-4931-AABD-A7DC1A3AE5CE

P478

Q34253290-582DA4FD-3FF4-4DDD-A3A6-16D514C8CC5D

P577

Q34253290-FF86FFC8-0190-40E7-BE52-1DE8F5D698CD

P698

Q34253290-8533B433-1AEE-4EAF-9F0A-A7CB33F079C5

P921

Q34253290-07114B77-2EB3-47E6-80E6-FE6ED1B2B6D1

P932

Q34253290-424AD836-425C-4933-8AD1-71B9312F427E

P356

P1433

Journal of Lipid Research

P1476

Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.

@en

P2093

Kerry-Anne Rye

http://www.w3.org/2001/XMLSchema#string

Philip J Barter

http://www.w3.org/2001/XMLSchema#string

P2860

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

Cloning and sequencing of human cholesteryl ester transfer protein cDNA

Purification and characterization of a human plasma cholesteryl ester transfer protein

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study

Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

P304

1755-1766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.R024075

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22550134

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3413218

http://www.w3.org/2001/XMLSchema#string